Combination treatment before and after surgery for stage III acral melanoma
Part of Cancer, Skin clinical trials.
This trial tests whether giving two drugs (QL1706 and OH2) before and after surgery can help treat stage III acral melanoma, a type of skin cancer on the palms, soles, or under nails. The goal is to see if this approach reduces the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage III acral melanoma that can be removed with surgery.
- You have at least one tumor that can be measured and is large enough for direct injection.
- You are generally healthy enough for surgery and treatment, with adequate organ function.
- You have not had previous treatment with certain immune checkpoint inhibitors (like anti-PD-1 or anti-CTLA-4).
- You agree to use effective birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This trial tests two medicines given before surgery to shrink stage III–IV acral melanoma (a melanoma type on the hands/feet) and improve outcomes. If the tumors respond, surgery can happen afterward as planned.
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
This trial tests a combination of two drugs, toripalimab (an immunotherapy) and endostatin (which targets blood vessels), given before and after surgery for stage II melanoma. The goal is to see if this combination helps prevent the cancer from coming back.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.